Attached files
| file | filename |
|---|---|
| 10-K - 10-K - KalVista Pharmaceuticals, Inc. | kalv-10k_20210430.htm |
| EX-32.2 - EX-32.2 - KalVista Pharmaceuticals, Inc. | kalv-ex322_6.htm |
| EX-32.1 - EX-32.1 - KalVista Pharmaceuticals, Inc. | kalv-ex321_10.htm |
| EX-31.2 - EX-31.2 - KalVista Pharmaceuticals, Inc. | kalv-ex312_12.htm |
| EX-31.1 - EX-31.1 - KalVista Pharmaceuticals, Inc. | kalv-ex311_11.htm |
| EX-10.21 - EX-10.21 - KalVista Pharmaceuticals, Inc. | kalv-ex1021_555.htm |
| EX-10.18 - EX-10.18 - KalVista Pharmaceuticals, Inc. | kalv-ex1018_356.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-215185, 333-217009, 333-228831, and 333-256378 on Form S-3 and Registration Statement Nos. 333-203721, 333-215184, 333-216032, 333-217008, 333-226442, 333-230279, 333-237059, and 333-254178 on Form S-8 of our report dated July 13, 2021, relating to the financial statements of KalVista Pharmaceuticals, Inc. appearing in this Annual Report on Form 10-K of KalVista Pharmaceuticals, Inc. for the year ended April 30, 2021.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
July 13, 2021